Haitron announced on the 5th that it has signed a strategic partnership agreement with GPCR, a targeted anticancer drug developer, to jointly promote projects including clinical trials for multiple ...
Shares of Structure Therapeutics are soaring Monday after the company reported positive topline data from a weight loss drug ...
TipRanks on MSN
Structure Therapeutics stock (GPCR) spikes 102% as obesity trial beats Eli Lilly, Novo Nordisk
Biotech Structure Therapeutics’ (GPCR) shares rallied 102.49% on Monday after mid-stage data for its obesity pill topped ...
Zacks Investment Research on MSN
GPCR stock soars 102% on strong phase II obesity data for Aleniglipron
Shares of Structure Therapeutics GPCR skyrocketed 102.5% after the company reported positive top-line data from the ACCESS ...
We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...
Septerna just entered the clinic, and its lack of human data makes it an outlier among the companies able to successfully go public this year in what is still a cautious biotech IPO market. What the ...
Septerna's GPCR-targeting platform could unlock novel therapies for a $125B market, with SEP-786 as lead asset. Analysts foresee potential from SEP-786 for hypoparathyroidism, with Phase 1 data ...
Septerna, Inc. (SEPN) has received a new Buy rating, initiated by TD Cowen analyst, Yaron Werber. Don't Miss our Black Friday Offers: Discover the latest stocks recommended by top Wall Street analysts ...
Most protein-targeting drugs are prizes that drug developers have unearthed from G protein–coupled receptor (GPCR) interactomes. So, when GPCR-targeting drugs become harder to find, one might liken ...
Announcing a new publication for Acta Materia Medica journal. G protein-coupled receptors (GPCRs) are important, potential drug targets for the treatment of metabolic disorders, such as obesity. GPCRs ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sosei Group Corporation ("Sosei Heptares"; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful ...
G protein-coupled receptors (GPCRs) represent the largest family of membrane proteins and one of the most successful therapeutic targets in modern medicine, with approximately 34% of FDA-approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback